Pivotal Phase 3 Study on Primary Hyperoxaluria Has High Quality Results
source: pixabay.com

Pivotal Phase 3 Study on Primary Hyperoxaluria Has High Quality Results

As seen in PR Newswire, researchers at the biopharmaceutical company OxThera AB have spent 52 weeks studying 25 patients with primary hyperoxaluria (PH), a rare disease that progressively damages the…

Continue Reading Pivotal Phase 3 Study on Primary Hyperoxaluria Has High Quality Results

UK Cystic Fibrosis Influencer Marc Cotterill Presents ‘Patient View’ Video at European Cystic Fibrosis Conference

Ahead of Cystic Fibrosis Week in the UK, 37-year-old Marc Cotterill, who lives with the disease, has given a video presentation to the European Cystic Fibrosis Conference on the theme…

Continue Reading UK Cystic Fibrosis Influencer Marc Cotterill Presents ‘Patient View’ Video at European Cystic Fibrosis Conference

Rare Disease Clinical Trials Are Essential to Help Uncover Potential Patient Solutions: Spotlight on Classic Congenital Adrenal Hyperplasia (CAH)

Acknowledgment: This story is sponsored by Neurocrine Biosciences and is promoted through the Patient Worthy Collaborative Content program. We only publish content that embodies our mission of providing relevant, vetted,…

Continue Reading Rare Disease Clinical Trials Are Essential to Help Uncover Potential Patient Solutions: Spotlight on Classic Congenital Adrenal Hyperplasia (CAH)
FDA Approves New Alzheimer’s Drug, But Not Without Controversy
source: pixabay.com

FDA Approves New Alzheimer’s Drug, But Not Without Controversy

According to an announcement from the US Food and Drug Administration (FDA), the agency has recently approved a new therapy for Alzheimer's disease. While this is a significant moment for…

Continue Reading FDA Approves New Alzheimer’s Drug, But Not Without Controversy
Real-World Data on Brigatinib as a Treatment for ALK+ Non-Small Cell Lung Cancer
source: pixabay.com

Real-World Data on Brigatinib as a Treatment for ALK+ Non-Small Cell Lung Cancer

Brigatinib has been approved for the treatment of ALK+ metastatic non-small cell lung cancer (NSCLC), as well as ALK+ NSCLC patients who have received prior treatment with crizotinib. While it…

Continue Reading Real-World Data on Brigatinib as a Treatment for ALK+ Non-Small Cell Lung Cancer
Benlysta Approved in Europe for Lupus Nephritis
https://pixabay.com/photos/hospital-infusion-hand-association-834157/

Benlysta Approved in Europe for Lupus Nephritis

  In early May 2021, pharmaceutical company GlaxoSmithKline shared that its therapy Benlysta (belimumab) was approved by the European Commission (EC) for expanded use in adult patients with lupus nephritis…

Continue Reading Benlysta Approved in Europe for Lupus Nephritis
Webinar: Is This Multidisciplinary Approach the Future of Brain Tumor Treatment?
source: pixabay.com

Webinar: Is This Multidisciplinary Approach the Future of Brain Tumor Treatment?

According to a story from yahoo.finance.com, the medical technology company iCAD, Inc. recently held a webinar featuring several brain tumor experts that discussed the potential of an approach called intraoperative…

Continue Reading Webinar: Is This Multidisciplinary Approach the Future of Brain Tumor Treatment?